Sunovion drug reduces hospitalization for lung disease
A post-hoc analysis of a long-term safety study of the effectiveness of Marlborough-based Sunovion Pharmaceuticals Inc.’s Brovana found the drug to be effective in reducing hospitalization in people with chronic obstructive pulmonary disease (COPD).
The study, carried out on patients with moderate-to-severe chronic obstructive pulmonary disease, took place over the course of a year and evaluated patients on Brovana versus a placebo. Brovana is a nebulized long-acting beta2 agonist administered twice daily that treats bronchoconstriction in people with COPD, including emphysema and chronic bronchitis.
Post hoc analyses found patients who received Brovana exhibited lower hospitalization rates related to COPD exacerbation than patients who took the placebo.
Patients who took Brovana also reported a reduction in hospitalization risk, with those results especially pronounced among patients achieving a minimum of a four point improvement on an index that quantifies health-related health status in patients with chronic airflow limitations. The index, called the St. George’s Respiratory Questionnaire, has a proven correlation with measures of symptom level, disease activity and disability.
WBJ Web Partners
Most Recent
Most Recent
0 Comments